Novo Nordisk Leads European Stock Market Thanks to Success of its Obesity Treatment
Pharmaceutical company Novo Nordisk has become the most valuable company on the stock exchange in Europe, surpassing the renowned French company LVMH (Louis Vuitton Möet Hennessy) thanks to its innovative obesity medication.
In a surprising victory, Novo Nordisk has reached a market value of $440.220 billion, leaving behind LVMH's $413.150 billion, according to Companies Market Cap data.
This rise is largely due to the launch of its obesity medication, Wegovy, in the United Kingdom on September 4, which resulted in a 3.98% increase in the value of the Danish company's shares.
Wegovy, a weekly injectable treatment that generates a feeling of fullness, has been in high demand worldwide, including in the United States since 2021.
This recent success has led Novo Nordisk to surpass in market value other prominent companies, such as American bank JP Morgan Chase, and to approach giants like Walmart and Exxon Mobil.
According to Companies Market Cap, Novo Nordisk now ranks 16th globally in capitalization, while LVMH is in 18th place.
In addition to Wegovy, Novo Nordisk also markets Ozempic, initially designed for diabetes treatment, but which has seen growth in its use to combat obesity in recent months.
Since the Food and Drug Administration (FDA) approval of Wegovy on June 4, 2021, Novo Nordisk shares have increased an impressive 177.31%, rising from 491.5 to 1,363.80 Danish krone.
Despite Novo Nordisk's great success in the obesity market, the company still ranks second among the largest pharmaceuticals on the stock exchange, surpassed only by American Eli Lilly, with a capitalization of $568.910 billion.
With information from: El Economista.
Receive all industry news in our weekly Newsletter Scientific Dialectics.